According to latest reports, Cipla's Q4 FY26 results showed significant deterioration with net profit plunging 55% year-over-year to ₹554.60 crore, while revenue declined 3% to ₹6,541.20 crore. EBITDA dropped 35% to ₹997 crore, with EBITDA margins compressing by 760 basis points year-over-year to 15.2%, down from 22.8% in the previous year's quarter. The margin compression stemmed from reduced contributions from high-value legacy products and increased research and development spending. R&D costs rose 20% year-over-year, reaching 7.8% of sales compared to 6.3% in Q4 FY25, with the company investing heavily in innovation despite short-term profitability impact.
As reported by Business Standard, Cipla delivered 2.2% year-on-year growth in revenue to ₹28,160 crore in FY26, with mixed regional performance driving overall results. The company's India business showed strong growth supported by in-licensing deals, including the Eli Lilly obesity drug and Pfizer's portfolio of Corex, Dolonex, and Neksium, which together contributed meaningfully to year-on-year growth. However, North America faced challenges with the loss of products like the generic version of Revlimid and Lanreotide due to regulatory issues, significantly impacting the region's performance. India experienced robust 15% year-over-year expansion, supported by significant in-licensing deals for products such as Eli Lilly's obesity drug and a Pfizer portfolio, with these in-licensed products adding an estimated 400-500 basis points to year-over-year growth. However, a sharp 26% contraction in North America, due to the loss of high-margin products like gRevlimid and the discontinuation of lanreotide, significantly impacted overall performance.
As reported by Business Standard, the company's gross margin contracted 430 basis points year-on-year to 63.2% and operating profit margin contracted 760 basis points year-on-year to 15.2%. Adjusted net profit declined 53.6% year-on-year to ₹570 crore, with depreciation and amortisation rising to ₹380 crore in Q4FY26 from ₹300 crore a year ago. The operating profit margin drop of 760 basis points was partly attributed to high research and development investments, with R&D increasing 20% year-on-year to 7.8% of sales from 6.3% of sales in Q4FY25. An extraordinary item of ₹42 crore includes impairment of investment in associates.
According to Business Standard, Cipla delivered 18 new launches in 9MFY26 and eight more in Q4FY26, with the company planning to file for four respiratory assets and three assets on the peptide and complex generic front over the next 24 months. The company has 55 abbreviated new drug applications (ANDA) pending approval and another 49 ANDAs tentatively approved. Management expects the US run rate to reach $250 million by Q4FY27 from the current $155 million, excluding possible upside from Lanreotide's potential revival. Key upcoming launches include generic versions of Ventolin, Advair, Symbicort, and teduglutide, with approval awaited for these products. The company's ambitious US revenue targets depend heavily on new product launches such as gVentolin, gAdvair, and teduglutide, with analysts noting that success in executing these launches will be critical for future financial performance.
According to latest reports, Cipla's stock showed immediate volatility with immediate positive reaction, trading up 8.05% to ₹1,434.00 amidst a trading volume of 9.79 million shares on the announcement day, suggesting investor relief or strategic repositioning. However, the preceding days showed a more cautious sentiment, with the stock price declining 7.4% over the last five trading days and dipping 0.97% on May 12, 2026. The stock's trailing twelve-month P/E ratio is around 23-25x, positioning it between peers like Dr. Reddy's Laboratories (P/E ~19.39) and Sun Pharmaceutical Industries (P/E ~40.31). Market sentiment remains cautious, with a neutral consensus rating and average price targets around ₹1,431.22. Nirmal Bang downgraded its rating to 'Hold' from 'Buy', and MarketsMojo issued a 'Sell' rating, reflecting concerns about growth and profit sustainability amid rising costs and competition. Despite analyst recommendations leaning towards 'Buy' or 'Hold' from firms like Citi (PT ₹1,700) and Nomura (PT ₹1,510), significant concerns persist about the sharp 55% year-over-year decline in net profit and margin compression.
According to Business Standard, Cipla maintains guidance for full-year FY27 operating profit margin in the range of 18.5-20%, with higher margins expected in H2FY27. The company has a large net cash position of ₹10,520 crore and intangible assets rising to ₹2,600 crore in FY26 from ₹1,300 crore in FY25. The FDA has completed inspections at three Cipla facilities, with all sites receiving either 'voluntary action indicated (VAI)' or 'no action indicated (NAI)' classifications. Management expects North American sales to rebound with low-mid teens annual growth between FY26 and FY28 to reach its target of $1 billion, supported by new respiratory assets and differentiated portfolio expansion. Cipla's success in executing US product launches, managing R&D spending, and navigating pricing pressures in key markets will be critical for future financial performance, with the company's strategy heavily relying on commercializing partnered assets in India and driving future US growth via its pipeline that must quickly deliver substantial returns to offset margin pressures.
